Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666366 | 0.87 | TSHR (0.39) | ALDH1A1 | |
| SCHEMBL666364 | 0.83 | — | — | |
| SCHEMBL20544238 | 0.81 | USP2 (0.34) | USP2MEN1KMT2A | |
| SCHEMBL304203 | 0.69 | TDP1 (0.54) | TDP1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL14528315 | 0.65 | HSD17B10 (0.50) | TDP1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL22985141 | 0.64 | LMNA (0.50) | TDP1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL1863345 | 0.64 | TDP1 (0.50) | TDP1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL1863343 | 0.64 | TDP1 (0.50) | TDP1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL14700391 | 0.64 | ALDH1A1 (0.45) | TDP1USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL6131221 | 0.63 | TDP1 (0.48) | TDP1USP2ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250189826-A1 | OPHTHALMIC DEVICES CONTAINING PHOTOSTABLE MIMICS OF MACULAR PIGMENT AND OTHER VISIBLE LIGHT FILTERS | JOHNSON & JOHNSON VISION CARE, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4363906-A1 | TRANSITION METAL COMPLEXES AS VISIBLE LIGHT ABSORBERS | Johnson & Johnson Vision Care, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275685-A1 | TRANSITION METAL COMPLEXES AS VISIBLE LIGHT ABSORBERS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-109415474-B | Silicone hydrogels comprising high levels of polyamides | 庄臣及庄臣视力保护公司 | 2022-05-10 | — | — | CN | disclosed |
| US-10073192-B2 | Polymers and nanogel materials and methods for making and using the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-9625617-B2 | Contact lenses comprising water soluble N-(2 hydroxyalkyl) (meth)acrylamide polymers or copolymers | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9522980-B2 | Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2014724-B9 | Wettable hydrogels comprising acyclic polyamides | JOHNSON & JOHNSON VISION CARE (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160161639-A1 | CONTACT LENSES COMPRISING WATER SOLUBLE N-(2 HYDROXYALKYL) (METH)ACRYLAMIDE POLYMERS OR COPOLYMERS | JOHNSON & JOHNSON VISION CARE (US) | 2016-06-09 | — | — | US | disclosed |
| EP-2014724-B1 | Wettable hydrogels comprising acyclic polyamides | JOHNSON & JOHNSON VISION CARE (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20130317131-A1 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130317132-A1 | CONTACT LENSES COMPRISING WATER SOLUBLE N-2 HYDROXYALKYL) (METH)ACRYLAMIDE POLYMERS OR COPOLYMERS | JOHNSON & JOHNSON VISION CARE (US) | 2013-11-28 | — | — | US | disclosed |
| US-8222353-B2 | Wettable hydrogels comprising acyclic polyamides | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110294914-A1 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES | JOHNSON & JOHNSON VISION CARE, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110275734-A1 | NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND METHODS FOR MAKING AND USING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. | 2011-11-10 | — | — | US | disclosed |
| US-8022158-B2 | Wettable hydrogels comprising acyclic polyamides | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7786185-B2 | Wettable hydrogels comprising acyclic polyamides | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100151123-A1 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES | JOHNSON & JOHNSON VISION CARE, INC. | 2010-06-17 | — | — | US | disclosed |
| EP-1720943-B1 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES | JOHNSON & JOHNSON VISION CARE (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080045612-A1 | Wettable hydrogels comprising acyclic polyamides | JOHNSON & JOHNSON VISION CARE, INC | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151123-A1 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES | CRYAA, UACA, CRYZ | TDP1 1142/4885USP2 360/4885ALDH1A1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.